**Table S2 (supplementary material online).** Predictors of first heart failure rehospitalization.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **HFpEF** Adjusted HR (95% CI), *p* | **HFmrEF**Adjusted HR (95% CI), *p* | **HFrEF**Adjusted HR (95% CI), *p* | *p* for interaction |
| **Baseline characteristics** |
| Age ≥65 years | 0.9 (0.7-1.3), 0.627 | 1.0 (0.7-1.4), 0.889 | 0.8 (0.6-0.9), 0.004 | 0.37 |
| Female sex | 1.0 (0.8-1.4), 0.845 | 1.2 (0.8-1.6), 0.418 | 1.0 (0.8-1.2), 0.693 | 0.66 |
| Body mass index ≥25 kg/m2 | 1.1 (0.8-1.5), 0.653 | 0.9 (0.6-1.4), 0.672 | 1.0 (0.8-1.3), 0.722 | 0.82 |
| Ischemic etiology of heart failure | 0.9 (0.6-1.2), 0.468 | 1.3 (0.9-1.8), 0.187 | 1.2 (1.0-1.5), 0.055 | 0.21 |
| Previous heart failure hospitalization | 1.4 (1.1-1.9), 0.013 | 1.5 (1.1-2.1), 0.020 | 1.3 (1.1-1.6), 0.001 | 0.76 |
| Previous stroke/TIA | 1.6 (1.1-2.3), 0.007 | 1.1 (0.6-1.8), 0.841 | 1.0 (0.8-1.3), 0.995 | **0.09** |
| History of atrial fibrillation | 1.7 (1.2-2.3), 0.002 | 1.9 (1.3-2.7), 0.001 | 1.1 (0.9-1.4), 0.197 | **0.01** |
| Peripheral vascular disease | 1.3 (0.9-1.8), 0.218 | 1.5 (1.0-2.4), 0.059 | 1.0 (0.8-1.2), 0.782 | 0.15 |
| Diabetes | 1.6 (1.2-2.2), <0.001 | 1.5 (1.0-2.1), 0.028 | 1.2 (1.0-1.4), 0.112 | **0.07** |
| Chronic obstructive pulmonary disease | 1.5 (1.1-2.0), 0.010 | 1.3 (0.9-2.0), 0.183 | 1.1 (0.9-1.4), 0.228 | 0.30 |
| Hepatic dysfunction | 1.2 (0.8-1.8), 0.469 | 1.7 (1.0-3.1), 0.066 | 1.2 (0.9-1.6), 0.200 | 0.53 |
| Cancer disease | 1.1 (0.6-1.9), 0.715 | 1.5 (0.8-2.8), 0.194 | 0.9 (0.6-1.4), 0.598 | 0.39 |
| Depression | 0.8 (0.5-1.3), 0.470 | 0.9 (0.4-1.8), 0.689 | 0.9 (0.6-1.2), 0.435 | 0.99 |
| **Reason for index heart failure decompensation** |
| Atrial fibrillation | 0.8 (0.6-1.1), 0.118 | 0.9 (0.7-1.4), 0.780 | 0.6 (0.5-0.8), <0.001 | **0.08** |
| Myocardial ischemia | 0.5 (0.3-0.9), 0.017 | 0.8 (0.5-1.2), 0.243 | 0.9 (0.7-1.1), 0.257 | 0.20 |
| Infection | 1.1 (0.8-1.5), 0.706 | 1.7 (1.1-2.5), 0.008 | 1.2 (0.9-1.5), 0.162 | 0.17 |
| Worsening renal function | 1.4 (1.0-1.9), 0.061 | 1.6 (1.0-2.4), 0.039 | 1.1 (0.9-1.4), 0.261 | 0.34 |
| Uncontrolled hypertension | 0.9 (0.6-1.3), 0.533 | 0.9 (0.6-1.4), 0.650 | 0.6 (0.4-0.9), 0.015 | 0.35 |
| **In-hospital findings (echocardiography) and in-hospital treatment** |
| Mitral regurgitation (moderate to severe) | 1.0 (0.7-1.3), 0.789 | 0.9 (0.6-1.3), 0.569 | 1.4 (1.1-1.6), 0.003 | **0.047** |
| Tricuspid regurgigation (moderate to severe) | 1.2 (0.9-1.6), 0.262 | 1.1 (0.8-1.6), 0.600 | 1.4 (1.1-1.6), 0.001 | 0.56 |
| Inotropic support | 1.4 (0.8-2.5), 0.183 | 0.6 (0.3-1.2), 0.157 | 1.3 (1.0-1.6), 0.026 | 0.12 |
| PCI/CABG | 0.9 (0.4-2.0), 0.722 | 0.8 (0.3-2.1), 0.728 | 0.7 (0.4-1.0), 0.064 | 0.81 |
| **Clinical and laboratory findings at discharge** |
| Heart rate ≥70 b.p.m. (for sinus rhythm)/ ≥80 b.p.m. (for AF) | 1.0 (0.8-1.3), 0.991 | 0.9 (0.6-1.3), 0.493 | 1.1 (1.0-1.4), 0.148 | 0.40 |
| Systolic blood pressure <110 mmHg | 1.3 (0.9-1.8), 0.200 | 1.0 (0.6-1.5), 0.881 | 1.3 (1.1-1.6), 0.004 | 0.45 |
| NYHA class III-IV | 1.1 (0.8-1.5), 0.739 | 1.9 (1.3-2.7), <0.001 | 1.0 (0.9-1.2), 0.770 | **0.008** |
| Hyponatremia (sodium <135 mmol/L) | 1.1 (0.7-1.8), 0.550 | 1.1 (0.7-1.7), 0.824 | 1.1 (0.9-1.4), 0.331 | 0.92 |
| eGFR <60 mL/min/1.73m2 | 1.3 (0.9-1.8), 0.102 | 1.4 (0.9-2.1), 0.110 | 1.2 (1.0-1.4), 0.108 | 0.84 |
| Anemia (hemoglobin <12 g/dL in women/ <13 g/dL in men) | 1.2 (0.9-1.6), 0.249 | 1.2 (0.8-1.7), 0.450 | 1.1 (0.9-1.3), 0.532 | 0.86 |
| **Pharmacotherapy at hospital discharge** |
| Diuretics | 3.4 (1.8-6.2), <0.001 | 1.3 (0.7-2.3), 0.405 | 1.1 (0.8-1.6), 0.622 | **0.008** |
| Aldosterone antagonists | 1.1 (0.8-1.5), 0.403 | 1.0 (0.7-1.4), 0.937 | 1.3 (1.1-1.6), 0.013 | 0.35 |
| ACEi/ARB/ARNIs | 0.8 (0.6-1.0), 0.066 | 0.9 (0.6-1.3), 0.517 | 0.8 (0.6-1.0), 0.030 | 0.84 |
| Beta-blockers | 1.0 (0.8-1.4), 0.938 | 1.4 (0.9-2.2), 0.105 | 0.8 (0.6-0.9), 0.011 | **0.02** |

Red *p*-values indicate significant differences between EF categories, orange *p*-values indicate a trend.

ACEi – angiotensin-converting enzyme inhibitor; AF – atrial fibrillation; ARB - angiotensin receptor blocker; ARNI - angiotensin receptor-nephrilysin inhibitor; b.p.m. – beats per minute; CABG – coronary artery bypass grafting; CI – confidence interval; EF – ejection fraction; eGFR – estimated glomerular filtration rate; HF – heart failure; HFmrEF – HF with mildly reduced ejection fraction; HFpEF – HF with preserved ejection fraction; HFrEF – HF with reduced ejection fraction; HR – hazard ratio; NYHA – New York Heart Association; PCI – percutaneous coronary intervention; TIA – transient ischemic attack